Pfizer Inc. (PFE, Financial) rose to prominence during the Covid-19 pandemic for its rapid development of a vaccine and antiviral therapy, establishing a household name in the process. As the pandemic faded, the stock lost over 50% of its value from its all-time high. However, the company legacy goes far beyond this. With a long history of pioneering invention, the pharmaceutical giant has continually provided life-saving solutions in fields such as oncology and cardiovascular care. Further, it has been mak ...

Upon authorization by the European Commission, the Omicron KP.2-adapted COVID-19 vaccine will be available for individuals 6 months of age and older Data demonstrate that the Omicron KP.2-adapted COVID-19 vaccine generates a substantially improved response against multiple circulating Omicron JN.1 sublineages as did the Omicron JN.1-adapted COVID-19 vaccine authorized by the European Commission in July 2024Doses will be ready to ship to applicable European Union member states as soon as possible upon Euro ...

Core Viewpoint - Pfizer's stock has shown a significant recovery, rising 7.3% over the past three months, outperforming both the industry and the S&P 500, despite previous struggles due to declining COVID-related product sales [1][2]. Sales Performance - Pfizer's sales from COVID products, Comirnaty and Paxlovid, have sharply declined in 2023, with a projected further decrease in 2024, estimating combined revenues of $8.5 billion compared to $12.5 billion in 2023 [3]. - Overall sales fell 42% in 2023 from a record high of $100 billion in 2022, raising concerns about long-term growth drivers beyond COVID-related products [2]. Growth Drivers - In 2023, Pfizer achieved a record number of FDA approvals, with nine new medicines and vaccines expected to drive future growth [4]. - Non-COVID operational revenues improved in the first half of 2024, supported by key products like Prevnar, Vyndaqel, and Eliquis, as well as new launches and acquisitions, including those from Seagen [4][5]. - Pfizer anticipates a revenue CAGR of approximately 6% from 2025 to 2030, bolstered by its late-stage pipeline and newly acquired products [4]. Oncology Position - Pfizer has a strong position in oncology, with oncology sales accounting for over 26% of total revenues and growing 23% on an operational basis in the first half of 2024 [6]. - The acquisition of Seagen has further strengthened Pfizer's oncology portfolio, with expectations of having eight or more blockbuster oncology medicines by 2030 [6]. Valuation and Earnings Estimates - Pfizer's stock is currently trading at a forward P/E ratio of 10.68, which is lower than the industry average of 19.77 and its own 5-year mean of 11.44, indicating an attractive valuation [7]. - The Zacks Consensus Estimate for earnings per share has increased from $2.39 to $2.62 for 2024 and from $2.75 to $2.85 for 2025 over the past 60 days, reflecting a positive outlook [8][9]. Investment Consideration - Pfizer is seen as gradually recovering from previous downturns, with non-COVID drugs and new product contributions driving growth [10]. - The company maintains a dividend yield of around 6% and expects to achieve savings of $4 billion in 2024 through cost cuts and restructuring [10]. - Rising earnings estimates suggest an optimistic outlook for Pfizer's growth potential, making it a candidate for investment at its current valuation [10].

The company's best days as a top pandemic vaccine supplier might be over, but it still has enough potential to be compelling.It was a rock star during the coronavirus pandemic, but Pfizer (PFE 2.73%) hasn't been the most exciting company in 2024. Its stock has become something of a value play, at least according to one analyst who released a fresh research note based on meetings with company management. He feels the stock has upside potential that's comfortably in the double-digit percentages. Here's why.An ...

KEY TAKEAWAYSPfizer said this weekend that a drug aimed at helping cancer patients losing appetite and muscle mass showed positive results in a Phase 2 trial.The pharma giant said ponsegromab will start late-stage trials next year. The drug aims to treat cancer cachexia, the life-threatening wasting condition that often affects patients with the disease. Pfizer (PFE) said this weekend that a drug aimed at helping cancer patients losing appetite and muscle mass showed positive results in a Phase 2 trial. The ...

Pfizer's sky-high dividend yield is tempting, but is it sustainable?High-yield dividend stocks offer two key benefits. They provide regular cash flow through dividend payments and, when dividends are consistently reinvested, have often outperformed the S&P 500 over extended periods.High yields, however, warrant scrutiny. They often result from falling share prices or overly generous payout policies. The payout ratio, which measures the proportion of earnings distributed as dividends, is a critical metric. R ...

Pfizer's experimental drug for a common, life-threatening condition that causes cancer patients to lose their appetite and weight showed positive results in a midstage trial, the drugmaker said Saturday. Patients with the condition, called cancer cachexia, who took Pfizer's treatment saw improvements in body weight, muscle mass, quality of life and physical function, according to the drugmaker. The results could pave the way for the drug, a monoclonal antibody called ponsegromab, to become the first treatme ...

Blister packets each containing a dose of PAXLOVID prescription medicine for a patient's Covid-19 ... [+] viral infection are arranged for a photo illustration on September 4, 2024 in Los Angeles, California. (Photo by Patrick T. Fallon / AFP) (Photo by PATRICK T. FALLON/AFP via Getty Images)AFP via Getty ImagesGiven its better valuation, we believe that Pfizer stock (NYSE: PFE) is currently a better pick than its industry peer – AbbVie stock . PFE stock trades at a much lower multiple of 11x forward, versu ...

Core Viewpoint - Pfizer (PFE) has received an upgrade to a Zacks Rank 2 (Buy), indicating a positive outlook on its earnings estimates, which is a significant factor influencing stock prices [1][2]. Earnings Outlook - The Zacks rating upgrade reflects optimism about Pfizer's earnings potential, which is expected to lead to increased buying pressure and a rise in stock price [2]. - Pfizer is projected to earn $2.62 per share for the fiscal year ending December 2024, representing a year-over-year increase of 42.4% [5]. Earnings Estimate Revisions - Over the past three months, the Zacks Consensus Estimate for Pfizer has increased by 12%, indicating a trend of rising earnings estimates [5]. - The correlation between earnings estimate revisions and near-term stock movements is strong, making it beneficial for investors to track these revisions [4]. Zacks Rank System - The Zacks Rank system classifies stocks into five groups based on earnings estimates, with Zacks Rank 1 (Strong Buy) stocks historically generating an average annual return of +25% since 1988 [4]. - Pfizer's upgrade to Zacks Rank 2 places it in the top 20% of Zacks-covered stocks, suggesting a strong potential for market-beating returns in the near term [7].

They're down but not out, at least not yet.The stock market has been on fire this year, but much of that performance can be attributed to a handful of tech giants that have a disproportionate weight of the S&P 500 and are benefiting from the artificial intelligence (AI) boom. Many other stocks have been doing well, but it's not that hard to find those moving in the opposite direction.Pharmaceutical giant Pfizer (PFE 1.12%) and social media platform Snap (SNAP 1.29%) belong to this group: Both have significa ...